岳岳欲试
Lv51
1020 积分
2024-01-28 加入
-
Immunotherapy plus tyrosine-kinase inhibitors in hepatocellular carcinoma
5小时前
已完结
-
BL-B01D1, a first-in-class EGFR–HER3 bispecific antibody–drug conjugate, in patients with locally advanced or metastatic solid tumours: a first-in-human, open-label, multicentre, phase 1 study
1个月前
已完结
-
Global alliances in translational cancer research
1个月前
已完结
-
Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma The DIPPER Randomized Clinical Trial
1个月前
已完结
-
First-line treatment for advanced NSCLC in older patients and those with poor performance status
6个月前
已完结
-
A prospective study of neoadjuvant pembrolizumab plus chemotherapy for resectable esophageal squamous cell carcinoma: The Keystone-001 trial
6个月前
已完结
-
PFS, OS or toxicity: What is the most important factor in the treatment of EGFR-mutated lung cancer?
6个月前
已关闭
-
Plinabulin plus docetaxel versus docetaxel in patients with non-small-cell lung cancer after disease progression on platinum-based regimen (DUBLIN-3): a phase 3, international, multicentre, single-blind, parallel group, randomised controlled trial
8个月前
已关闭
-
非小细胞肺癌新辅助治疗疗效病理评估专家共识
9个月前
已完结
-
New promises and challenges in the treatment of advanced non-small-cell lung cancer
9个月前
已完结